ADMP Split History

Adamis Pharmaceuticals (ADMP) has 1 split in our ADMP split history database. The split for ADMP took place on December 13, 2013. This was a 1 for 17 reverse split, meaning for each 17 shares of ADMP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 58.8235294117647 share position following the split.

When a company such as Adamis Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ADMP split history from start to finish, an original position size of 1000 shares would have turned into 58.8235294117647 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adamis Pharmaceuticals shares, starting with a $10,000 purchase of ADMP, presented on a split-history-adjusted basis factoring in the complete ADMP split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	11/27/2012
End date:	11/25/2022
Start price/share:	$15.47
End price/share:	$0.19
Dividends collected/share:	$0.00
Total return:	-98.77%
Average Annual Total Return:	-35.59%
Starting investment:	$10,000.00
Ending investment:	$122.89
Years:	10.00

About Adamis Pharmaceuticals

Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates in the allergy, respiratory, and opioid overdose markets include: SYMJEPI™ (epinephrine) Injection 0.3mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis; ZIMHI™ (naloxone HCL Injection, USP) five mg/0.5 mL for the treatment of opioid overdose; and Tempol, an investigational drug. Co. also has a microbicide product candidate, named C31G. According to our ADMP split history records, Adamis Pharmaceuticals has had 1 split.